

**THIS DOCUMENT IS IMPORTANT AND NEEDS YOUR IMMEDIATE ATTENTION.** If you are in any doubt as to the action you should take with regard to this document or its enclosures, you are recommended to seek your own personal financial advice from your stockbroker, solicitor, accountant or other professional independent adviser who, if you are taking advice in the United Kingdom, is duly authorised under the Financial Services and Markets Act 2000 or an appropriately authorised independent financial adviser if you are in a territory outside the United Kingdom. If you have sold or otherwise transferred all your shares in Morgan Advanced Materials plc, you should send this document to the purchaser or transferee or to the stockbroker, bank or other agent through whom you made the sale or transfer for transmission to the purchaser or transferee.



**Morgan Advanced Materials plc**  
**NOTICE OF**  
**ANNUAL GENERAL MEETING 2026**

A letter from the Chair of Morgan Advanced Materials plc is set out on page 1 of this document.

Notice of the Annual General Meeting of Morgan Advanced Materials plc to be held at Slaughter and May's Offices, One Bunhill Row London EC1Y 8YY on Thursday 7 May 2026 at 10.30am is set out on pages 2 and 3 of this document.

Please complete and submit a proxy appointment in accordance with the Notes to the Notice of the Annual General Meeting set out on pages 8 and 9. To be valid, the proxy appointment must be received at the address for delivery specified in the Notes by 10.30am on Tuesday 5 May 2026.

Registered Office:  
York House  
Sheet Street  
Windsor  
Berkshire SL4 1DD  
26 March 2026

To holders of Ordinary shares of 25 pence each (Ordinary shares) and for information only to holders of 5.5% Cumulative First Preference shares of £1 each (First Preference shares) and 5.0% Cumulative Second Preference shares of £1 each (Second Preference shares).

Dear Shareholder

## **2026 ANNUAL GENERAL MEETING**

I am pleased to be writing to you with details of the 2026 Annual General Meeting (AGM) of Morgan Advanced Materials plc (the Company) which will be held at Slaughter and May's Offices, One Bunhill Row, London EC1Y 8YY on Thursday 7 May 2026 at 10.30am.

Notice of the AGM can be found on pages 2 and 3 of this document and contains the proposed resolutions on which you are invited to vote. The Explanatory Notes to the business of the AGM are set out on pages 4 to 7.

### **Voting at the AGM**

Only holders of Ordinary shares, their proxies or duly authorised representatives may vote at the AGM. All of your votes are important to us and, once again this year, you will be asked to vote on each of the resolutions on a poll, as permitted by the Articles of Association. On a poll, each shareholder has one vote for every share held. Voting on a poll ensures a more accurate reflection of the views of shareholders as every vote is counted.

If you are unable to attend the AGM in person, you can still be represented at the meeting by appointing a proxy to act on your behalf and by giving instructions on how you wish to vote. Whether or not you plan to attend the AGM, I would encourage you to vote on the proposed resolutions by appointing a proxy to ensure that your vote is counted if you are unable, for any reason, to attend on the day. Appointing a proxy will not prevent you from attending the meeting and voting in person if you so choose. You can appoint a proxy by:

- > Going to [shareview.co.uk](https://shareview.co.uk), logging into your Shareview Portfolio and submitting a proxy appointment online by following the instructions; or
- > If you are an institutional investor, submitting a proxy appointment electronically via the Proxymity platform; or
- > If you are a CREST member, submitting a proxy appointment electronically by using the CREST voting service.

In each case, any proxy appointments must be submitted to the Company's registrar, Equiniti, no later than 10.30am on Tuesday 5 May 2026 for your vote to be registered. If you would prefer to use a paper proxy form to appoint your proxy, you may request one from Equiniti by calling +44 (0) 371 384 2412. Further information on how to appoint a proxy to vote on your behalf is set out in the Notes to the Notice of AGM.

The voting results will be announced through a Regulatory Information Service and published on our website as soon as possible following the AGM.

### **Asking questions**

The Board recognises the importance of the AGM to shareholders and is keen to ensure you are able to exercise your rights to engage and participate in the meeting. Shareholders, or their appointed proxies or duly authorised representatives who attend the AGM, will be able to ask questions on the business of the meeting. All shareholders, irrespective of whether or not they plan to attend the AGM, are also invited to ask questions on the business of the AGM in advance of the meeting, by emailing [company.secretariat@morganplc.com](mailto:company.secretariat@morganplc.com), or by writing to the Company Secretary at our registered office address. The Company Secretary will respond to those questions and publish answers on the Company's website. To ensure answers are published before the proxy appointment deadline, questions must be received before 5.00pm UK time on Monday 27 April 2026.

### **Recommendation**

Your Directors consider that the proposed resolutions as set out in the Notice and to be put to the meeting will promote the success of the Company and are in the best interests of the Company and its shareholders as a whole, and accordingly, unanimously recommend that you vote in favour of them, as they intend to do so in respect of their own beneficial shareholdings (other than in respect of resolutions in which they hold an interest).

On behalf of the Board, I would like to thank you for your continued support.

Yours faithfully

**Ian Marchant**  
Chair

# Morgan Advanced Materials plc

(Registered in England and Wales No. 00286773)

## NOTICE OF ANNUAL GENERAL MEETING

Notice is given that the ninety-second AGM of Morgan Advanced Materials plc (the "Company") will be held at Slaughter and May's Offices, One Bunhill Row, London EC1Y 8YY on Thursday 7 May 2026 at 10.30am to transact the business set out below. Resolutions 1 to 14 will be proposed as ordinary resolutions and resolutions 15 to 18 will be proposed as special resolutions.

### Ordinary resolutions:

1. To receive the audited accounts and the Auditor's and Directors' Reports for the year ended 31 December 2025.
2. To approve the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy) for the year ended 31 December 2025.
3. To declare a final dividend of 6.8 pence per Ordinary share.
4. To re-elect Richard Armitage as a Director.
5. To re-elect Damien Caby as a Director.
6. To re-elect Ian Marchant as a Director.
7. To re-elect Alison Wood as a Director.
8. To re-elect Clement Woon as a Director.
9. To elect Jane Lodge as a Director.
10. To elect Professor Mary Ryan CBE FREng as a Director.
11. To re-appoint Deloitte LLP as Auditor of the Company.
12. To authorise the Audit Committee of the Board of Directors to determine the Auditor's remuneration.
13. That, from the date of this resolution until the earlier of the close of business on 30 June 2027 and the conclusion of the Company's Annual General Meeting to be held in 2027, the Company and all companies which are its subsidiaries at any time during such period are authorised:
  - a) to make donations to political parties and/or independent election candidates;
  - b) to make donations to political organisations other than political parties; and
  - c) to incur political expenditure,up to an aggregate total amount of £100,000, with the amount authorised for each of paragraphs a) to c) above being limited to the same total.

Any such amounts may comprise sums paid or incurred in one or more currencies. Any sum paid or incurred in a currency other than sterling shall be converted into sterling at such rate as the Board may decide is appropriate.

Terms used in this resolution have, where applicable, the meanings that they have in Part 14 of the Companies Act 2006 on 'Control of political donations and expenditure'.
14. That the Directors are generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into such shares in the Company:
  - a) up to an aggregate nominal amount of £23,056,367 (such amount to be reduced by the aggregate nominal amount of any equity securities that may be allotted pursuant to paragraph b) below in excess of £23,056,367); and
  - b) comprising equity securities (as defined in section 560(1) of the Companies Act 2006), up to an aggregate nominal amount of £46,112,734 (such amount to be reduced by the aggregate nominal amount of shares allotted or rights granted pursuant to paragraph a) above) in connection with a fully pre-emptive offer:
    - i) to holders of Ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers of Ordinary shares held by them; and
    - ii) to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to such rights, as the Directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of any regulatory body or stock exchange, provided that (unless previously revoked, varied or renewed) this authority shall expire at the close of business on 30 June 2027 or, if earlier, at the conclusion of the Company's AGM to be held in 2027, save that the Company may make any offer or agreement before such expiry which would or might require shares to be allotted or rights to be granted after such expiry and the Directors may allot shares or grant rights under any such offer or agreement as if the authority had not expired. All authorities vested in the Directors on the date of the Notice of this meeting to allot shares or to grant rights that remain unexercised at the commencement of this meeting are revoked.

### Special resolutions:

15. That, subject to the passing of resolution 14 in the Notice of this meeting, the Directors are empowered pursuant to sections 570 and 573 of the Companies Act 2006 to allot equity securities (as defined in section 560(1) of the Companies Act 2006) for cash under the authority given by resolution 14 and/or to sell Ordinary shares held by the Company as treasury shares for cash as if section 561 of the Companies Act 2006 did not apply to any such allotment and/or sale, provided that such power is limited to:

- a) the allotment of equity securities and/or sale of treasury shares in connection with an offer of securities (but in the case of the authority granted under paragraph b) of resolution 14 in connection with a fully pre-emptive offer only) in favour of holders of Ordinary shares in the capital of the Company at such record date as the Directors may determine and other persons entitled to participate therein where the equity securities respectively attributable to the interests of such holders are proportionate (as nearly practicable) to the respective number of Ordinary shares in the capital of the Company held by them on any such record date, subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of any relevant regulatory body or stock exchange; and
- b) the allotment of equity securities and/or sale of treasury shares (otherwise than under paragraph a) above) up to a nominal amount of £6,916,910;

and shall expire on the revocation or expiry (unless renewed) of the authority conferred on the Directors by resolution 14 in the Notice of this meeting, save that, prior to the expiry of this power the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and/or treasury shares to be sold) after the power expires and the Directors may allot equity securities (and/or sell treasury shares) under any such offer or agreement as if the power had not expired.

16. That, subject to the passing of resolution 14 in the Notice of this meeting and in addition to any power granted under resolution 15 in the Notice of this meeting, the Directors are empowered pursuant to sections 570 and 573 of the Companies Act 2006 to allot equity securities (as defined in section 560(1) of the Companies Act 2006) for cash under the authority given by resolution 14 and/or to sell Ordinary shares held by the Company as treasury shares for cash as if section 561 of the Companies Act 2006 did not apply to any such allotment and/or sale, provided that such power is:

- a) limited to the allotment of equity securities and/or sale of treasury shares up to an aggregate nominal amount of £6,916,910; and
- b) used only for the purposes of financing (or refinancing, if the power is to be used within 12 months after the original transaction) a transaction which the Directors determine to be either an acquisition or a specified capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of the Notice of this meeting,

and shall expire on the revocation or expiry (unless renewed) of the authority conferred on the Directors by resolution 14 in the Notice of this meeting, save that, prior to the expiry of this power, the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and/or treasury shares to be sold) after the power expires and the Directors may allot equity securities (and/or sell treasury shares) under any such offer or agreement as if the power had not expired.

17. That the Company is generally and unconditionally authorised pursuant to section 701 of the Companies Act 2006 to make market purchases, as defined in section 693(4) of the Companies Act 2006, of the Company's Ordinary shares on such terms and in such manner as the Directors may from time to time determine, provided that:

- a) the maximum aggregate number of Ordinary shares hereby authorised to be purchased is 27,667,640;
- b) the minimum price (exclusive of expenses) that may be paid for each Ordinary share is its nominal value;
- c) the maximum price (exclusive of expenses) which may be paid for each Ordinary share shall be an amount equal to the higher of:
  - i) 5 per cent above the average market value of an Ordinary share for the five business days immediately preceding the day on which that Ordinary share is contracted to be purchased; and
  - ii) the higher of the price of the last independent trade and the highest current independent bid for an Ordinary share on the trading venue where the purchase is to be carried out, including when the shares are traded on different trading venues;
- d) such authority will expire at the close of business on 30 June 2027 or, if earlier, at the conclusion of the Company's AGM to be held in 2027; and
- e) before such expiry the Company may enter into a contract to purchase Ordinary shares that would or might be completed or executed wholly or partly after such expiry and the Company may purchase Ordinary shares pursuant to any such contract as if the authority had not expired.

18. That a general meeting of the Company, other than an AGM, may be called on not less than 14 clear days' notice.

Registered office:  
York House, Sheet Street  
Windsor, Berkshire SL4 1DD

By Order of the Board  
**Winifred Chime**  
**Company Secretary**  
26 March 2026

# EXPLANATORY NOTES TO THE BUSINESS OF THE ANNUAL GENERAL MEETING

---

## **Resolution 1 – Receipt of the Annual Report and Accounts**

The Companies Act 2006 requires the directors of a public company to lay before the company in general meeting copies of the directors' reports, the independent auditor's report and the audited accounts of the company in respect of each financial year. In line with best practice, the Company proposes a resolution on its audited accounts and reports for the financial year ended 31 December 2025 (the "2025 Annual Report and Accounts").

## **Resolution 2 – Approval of the Directors' Remuneration Report**

In accordance with the Companies Act 2006, shareholders are invited to approve the Directors' Remuneration Report, which is set out on pages 78 to 104 of the 2025 Annual Report and Accounts. For the purposes of this resolution, the Directors' Remuneration Report does not include the Directors' Remuneration Policy set out on pages 81 to 89. The vote on the Directors' Remuneration Report is advisory only and the Directors' entitlement to remuneration is not conditional on it being passed.

The Companies Act 2006 requires that the Directors' Remuneration Policy must be put to shareholders for approval whenever a new policy, or an amendment to an existing approved policy, is proposed. The Directors' Remuneration Policy must in any event be put to shareholders for approval at least every three years. The Company is not proposing any changes to the Directors' Remuneration Policy approved at the Annual General Meeting in 2025.

## **Resolution 3 – Final dividend**

The Directors are recommending the payment of a final dividend of 6.8 pence per share on the Ordinary shares in respect of the year ended 31 December 2025 which, if approved, will be payable on 12 May 2026 to shareholders on the register at the close of business on 10 April 2026. The Company is not offering a scrip alternative to the cash dividend.

## **Resolutions 4 to 10 – Re-election and election of Directors**

Resolutions 4 to 10 relate to the re-election and election of the Company's Directors.

In accordance with the provisions of the UK Corporate Governance Code ("Code") and as permitted by the Company's Articles of Association, the Board has decided that all Directors as at the date of the Notice of this meeting will retire from office at the AGM and each of them will seek re-election or election, as appropriate, by shareholders with the exception of Jane Aikman who as previously announced will not be standing for re-election and will be stepping down from the Board upon conclusion of this year's AGM, having reached the end of her nine-year term.

Any Director appointed since the Company's last AGM must be elected by shareholders. Jane Lodge was appointed in June 2025 and Professor Mary Ryan CBE FREng was appointed in November 2025, and they will both therefore be standing for election at this year's AGM.

All of the non-executive Directors standing for re-election and election are considered to be independent. It is the opinion of the Board, supported by the results of the internal Board performance review in 2025, that each Director continues to be effective, demonstrating continued significant commitment to their roles. The Board believes that the considerable and wide-ranging experience of the Directors seeking re-election or election, as appropriate, is invaluable and their contribution continues to be an important part of the Company's long-term sustainable success. The skills, contribution and experience of the Directors are set out below and on pages 57 and 58 of the 2025 Annual Report and Accounts.

### **Richard Armitage, CFO**

**Skills and contribution:** Richard has broad experience including financial management, investor relations, capital markets, M&A and commercial management, gained through roles at several listed and privately owned chemicals and consumer goods companies.

**Past experience:** Prior to joining Morgan Advanced Materials, Richard was CFO at Victrex Group plc from 2018 to 2022. During this time, he was responsible for finance, IT, legal and corporate development, as well as the development of the Group's Chinese businesses. Richard was CFO of Samworth Brothers from 2014 to 2018 and CFO of McBride plc from 2009 to 2014.

**External appointments:** Senior Independent Director and Chair of the Audit Committee at NWF Group plc.

### **Damien Caby, CEO**

**Skills and contribution:** Damien brings strong leadership skills and extensive business experience in specialities across several markets. He has an established track record of strategic organic and inorganic growth, innovation and transformation of global advanced materials and processing aids and a strong technical and international background, having lived and worked in the United States, Germany and France.

**Past experience:** Before joining Morgan Advanced Materials in 2022 as President of the Thermal Products Division, Damien held senior business group and business leadership roles at BASF from 2017 to 2022 and Imerys from 2011 to 2016.

**External appointments:** None.

### **Ian Marchant, Non-executive Chair and Nomination Committee Chair**

**Skills and contribution:** Ian is a highly strategic and successful leader with more than 35 years of wide-ranging experience at major businesses, bringing a strong track record of value creation and listed board experience. Ian has significant expertise in governance, finance, regulation, renewable energy and climate change mitigation.

**Past experience:** Ian served as CEO of SSE plc from October 2002 to June 2013; prior to this he was Finance Director of SSE and Southern Electric plc. He is a seasoned non-executive Director and Chair, having served as Chair of Thames Water Utilities Ltd and John Wood Group plc and on the Board of Aggreko plc.

**External appointments:** Non-executive Director of Fred. Olsen Ltd and arbnco Ltd and a member of the Prince's Council of the Duchy of Cornwall.

### **Alison Wood, Senior Independent Director and Remuneration Committee Chair**

**Skills and contribution:** Alison is a highly experienced non-executive Director with a significant background in international industrials. She brings deep governance expertise gained across numerous listed businesses, having served as Chair, Senior Independent Director and Remuneration Committee Chair of several FTSE 350 businesses.

**Past experience:** In her executive career, Alison was Global Director of Strategy and Corporate Development at National Grid plc from 2008 to 2013. She was central to the strategic development of BAE Systems plc in her role as Group Strategic Development Director from 2004 to 2008. Alison was a non-executive Director of TT Electronics plc from 2016 to 2025 and served as Chair of their Remuneration Committee.

**External appointments:** Chair of Galliford Try Holdings plc, Senior Independent Director and Remuneration Committee Chair of Oxford Instruments plc.

### **Clement Woon, Independent non-executive Director**

**Skills and contribution:** Clement has broad managerial experience in globally operating technology and consumer-related industries. He has a strong track record of renewing traditional industries and revitalising growth through strategic interventions, and in-depth experience and knowledge of markets within the Asia Pacific region.

**Past experience:** From August 2016 to March 2020, Clement was Group CEO of Saurer Intelligent Technology Co. Ltd, a €1 billion textile machinery and components business listed on the Shanghai Stock Exchange. Clement continued to serve on the board of Saurer as non-executive Director until August 2021. Prior to this, Clement was Advisor and Co-CEO of Jinsheng Industry Co Ltd, an industrial company in China with diverse interests including biotech, automotive and textiles. Previously Clement held various senior positions including Division CEO of Leica Geosystems AG, President and CEO of SATS Ltd, and CEO Textile Division of OC Oerlikon AG.

**External appointments:** Non-executive Director and Remuneration Committee Chair of Elementis plc.

### **Jane Lodge, Independent non-executive Director**

**Skills and contribution:** Jane is a highly experienced non-executive Director and Audit Committee Chair with a significant background in international businesses in the industrial/manufacturing sector. Jane is a Chartered Accountant with substantial audit, risk and financial experience. Jane will succeed Jane Aikman as Audit Committee Chair following the AGM.

**Past experience:** In her executive career, Jane spent 35 years at Deloitte & Touche LLP, progressing to a Senior Audit Partner working for major corporates and acted as the manufacturing and industry lead Partner, providing best practice and insights across tax, auditing, consulting and corporate finance. Jane was previously a Non-executive Director and Audit Committee Chair of TI Fluid Systems plc from 2022 to 2025, Non-executive Director of DCC plc from 2012 to 2022, Senior Independent Director and Audit Committee Chair of Costain Group plc from 2012 to 2021, Non-executive Director and Audit Committee Chair of Devro plc from 2012 to 2021.

**External appointments:** Non-executive Director and Audit Committee Chair of First Group plc, Non-executive Director and Remuneration Committee Chair of Glanbia plc and Non-executive Director and Audit and Risk Committee Chair of Bakkavor Group Plc.

### **Professor Mary Ryan CBE FEng, Independent non-executive Director**

**Skills and experience:** Mary brings significant materials science expertise to the Board. She is a leading materials scientist at Imperial College London ("Imperial"), where she currently serves as Vice-Provost for Research and Enterprise and the Armourers & Brasiers' Chair in Materials Science. She has significant industry exposure, having led Imperial's partnerships with several major corporates including Shell, Rio Tinto and Hitachi. She is a Fellow of the Royal Academy of Engineering and Fellow of the Institute of Materials, Minerals and Mining (IoM3).

**Past experience:** Mary has held various senior positions in Imperial, since joining Imperial in 1998.

**External appointments:** Vice-Provost for Research and Enterprise and the Armourers and Brasiers' Chair for Materials Science at Imperial, Non-executive director of the UK Atomic Energy Authority Board, Board member of the Francis Crick Institute and Governing Board member of the Henry Royce Institute.

### **Resolutions 11 and 12 – Auditor re-appointment and remuneration**

At each meeting at which the Annual Report and Accounts are laid, the Company is required to appoint an auditor to serve until the next such meeting. The Audit Committee has recommended to the Board, and the Board now proposes to shareholders, the re-appointment of Deloitte LLP as the Company's Auditor. The Audit Committee has confirmed to the Board that its recommendation is free from third party influence and that no restrictive contractual provisions have been imposed on the Company limiting the choice of auditor. Resolution 12 is a resolution giving the Audit Committee the discretion to determine the Auditor's remuneration.

### **Resolution 13 – Political donations and expenditure**

This resolution renews a similar authority given at last year's AGM and which is due to lapse at the AGM. It seeks approval from shareholders to enable the Company, and all companies which are, or which become, subsidiaries of the Company, to make political donations and incur political expenditure which it would otherwise be prohibited from making or incurring by the Companies Act 2006.

The Company's policy is not to make donations to political parties nor to incur political expenditure and there is no intention to change that policy. However, the Companies Act 2006 defines political expenditure, political donations and political organisations very widely, such that normal business activities, which might not be thought to be political expenditure or a political donation to a political organisation in the usual sense, may be included. For example, sponsorship of industry forums, funding of seminars and other functions to which politicians are invited, matching employees' donations to certain charities, expenditure on organisations concerned with matters of public policy, law reform and representation of the business community and communicating with the Government and political parties at local, regional and national level, may fall under the terms of the Companies Act 2006.

Accordingly, the Company, in common with many other companies, seeks an authority to make political donations as well as to incur political expenditure, to cover these kinds of activities on a precautionary basis, in order to avoid possible inadvertent contravention of the Companies Act 2006. The authority does not purport to authorise any particular donation or expenditure but is expressed in general terms, as required by the Companies Act 2006. Furthermore, as permitted under that Act, the authority has been extended to cover any political donations made and political expenditure incurred by any subsidiaries of the Company. Therefore, as a precautionary measure, you will be asked to give the Company and each of its subsidiaries authority to make political donations to political parties or independent election candidates, to make political donations to political organisations (other than political parties) and to incur political expenditure. This authority is limited to a maximum aggregate amount of £100,000.

If given, this authority will expire on the earlier of the close of business on 30 June 2027 and the conclusion of the Company's AGM to be held in 2027. It is the Directors' intention to renew this authority each year.

### **Resolution 14 – Authority to allot shares**

The Directors currently have an authority to allot shares in the Company and to grant rights to subscribe for or convert any securities into shares in the Company. This authority is due to lapse at the AGM. The Board is seeking to renew that authority over Ordinary shares up to an aggregate nominal amount of £23,056,367, representing approximately one third of the issued Ordinary share capital of the Company and also to give the Directors authority to allot Ordinary shares up to an aggregate nominal amount of £46,112,734, representing approximately two thirds of the issued Ordinary share capital of the Company, by way of a fully pre-emptive offer (as permitted by the most recent version of The Investment Association's Share Capital Management Guidelines). For the avoidance of doubt, the authority sought pursuant to this resolution will give the Directors the ability to allot shares (or grant rights to shares) up to a maximum aggregate nominal amount of £46,112,734. The authority will lapse at the close of business on 30 June 2027 or at the AGM to be held in 2027, whichever shall first occur. The authority sought under this resolution is standard for most UK listed companies and is within the limits prescribed by The Investment Association. The Directors have no present intention to allot any shares under the authority being sought. Each reference in this explanatory note to the Company's issued Ordinary share capital is to the issued Ordinary share capital of the Company as at 10 March 2026 (being the latest practicable date prior to the publication of this document). The Company did not hold any shares in treasury as at that date.

### **Resolutions 15 and 16 – Disapplication of statutory pre-emption rights**

These are special resolutions which, if passed by shareholders, will enable the Board to allot Ordinary shares, or to sell any shares out of treasury, for cash, without first offering those shares to existing shareholders in proportion to their existing holdings.

In November 2022, the Pre-Emption Group revised its Statement of Principles on the Disapplication of Pre-emption Rights (the "Principles"). The Principles incorporated a number of changes designed to improve capital raising processes for publicly traded companies by, among other matters, increasing the "routine" disapplication thresholds and introducing new supplemental disapplication thresholds.

The Principles provide that a company may seek power to issue, on a non-pre-emptive basis, shares for cash in any one year representing: (i) no more than 10% (previously 5%) of the company's issued ordinary share capital for use in any circumstances; and (ii) no more than an additional 10% (previously 5%) of the company's issued ordinary share capital provided that such additional power is only used in connection with an acquisition or specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding 12 month period (previously 6 months) and is disclosed in the announcement of the issue.

The Principles also provide that, in both cases (i) and (ii) outlined above, a company may now seek a further power to issue, on a non-pre-emptive basis, shares for cash representing no more than 2% of the company's issued ordinary share capital for the purposes of making a "follow-on" offer (being an offer of a kind contemplated by the Principles) to certain retail investors and existing shareholders.

The Directors have again carefully considered the increased and supplemental thresholds available under the Principles and have concluded that it continues to be in the best interests of the Company and its shareholders generally that the Company has the maximum flexibility conferred by the increased "routine" thresholds in order to react quickly and efficiently should the needs of the business require. The Directors have no current plans, however, to exercise these authorities.

As was the case last year, the Directors are not seeking the supplemental thresholds notwithstanding the fact that this would be permissible under the Principles. The Directors will review this annually to ensure that the powers sought remain in the Company's best interests.

Resolution 15 is proposed as a special resolution. If this resolution is passed by shareholders, it will permit the Directors to allot Ordinary shares for cash on a non-pre-emptive basis both in connection with a rights issue or similar pre-emptive issue and, otherwise than in connection with any such issue, up to a maximum nominal amount of £6,916,910. This amount represented approximately 10% of the Company's issued Ordinary share capital as at 10 March 2026 (being the latest practicable date prior to publication of this document). This resolution will permit the Board to allot any such shares for cash in any circumstances (whether or not in connection with an acquisition or specified capital investment).

Resolution 16 is proposed as a separate special resolution. If this resolution is passed by shareholders, it will afford the Directors an additional power to allot Ordinary shares for cash on a non-pre-emptive basis up to a further maximum nominal amount of £6,916,910. This amount also represented approximately 10% of the Company's issued Ordinary share capital as at 10 March 2026. The Board will use the power conferred by resolution 16 only in connection with an acquisition or a specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding 12 months period and is disclosed in the announcement of the issue.

The Directors confirm that, in exercising these powers, they will follow the shareholder protections and features set out in Part 2B of the Principles.

#### **Resolution 17 – Purchase of own shares**

The proposed resolution (which will be proposed as a special resolution) seeks authority for the Company to purchase up to a maximum of 27,667,640 of its own Ordinary shares (that is approximately 10% of the Company's issued Ordinary share capital, and therefore within institutional shareholder guidelines, as at 10 March 2026). The resolution specifies the maximum and minimum prices at which Ordinary shares may be bought. This authority will expire at the conclusion of the AGM of the Company to be held in 2027 or at the close of business on 30 June 2027, whichever is earlier.

The Directors are seeking this authority as they consider it prudent for the Company to have the flexibility in its financial management to make market purchases of its own Ordinary shares, despite having no present intention of using the authority sought in this resolution. The Directors confirm that they will exercise this authority only when, in light of the prevailing market conditions, the Directors (i) expect that such a buyback would result in an increase in earnings per share, (ii) consider that the Company has excess cash, and/or (iii) determine that it is appropriate to increase the Company's gearing.

Any Ordinary shares purchased by the Company under this authority would either be cancelled or held as treasury shares, depending on which course of action is considered by the Directors to be in the best interests of shareholders at that time. Treasury shares may subsequently be cancelled, sold for cash or used to satisfy options and awards granted to employees pursuant to the Company's employee share schemes. Once held in treasury, the Company is not entitled to exercise any rights, including the right to attend and vote at meetings, in respect of the shares. Further, no dividend or other distribution of the Company's assets may be made to the Company in respect of the treasury shares.

On 5 November 2024, the Company announced a share buyback programme (the Buyback Programme) to return up to £40 million (excluding expenses) of capital to shareholders, with the first tranche of the Buyback Programme (Tranche 1) to purchase up to a maximum of £10 million (excluding expenses) of capital commencing on the same day. Tranche 1 of the Buyback Programme completed on 4 March 2025 and the second tranche of the Buyback Programme (Tranche 2) to purchase up to a maximum of £10 million of capital (excluding expenses) completed on 9 January 2026, each undertaken within the Company's general authorities to purchase its own Ordinary shares granted by shareholders at the 2024 and 2025 AGMs. As announced on 4 December 2025, the Company paused the Buyback Programme following completion of Tranche 2, as part of the focus on balance sheet resilience. The Company purchased and cancelled 8,693,579 Ordinary shares under the Buyback Programme, for a consideration of approximately £19,999,948 (excluding expenses).

As at 10 March 2026, there were options and awards outstanding to subscribe for 9,113,429 Ordinary shares under the Company's shareholder approved employee share schemes. If the outstanding options and awards were fully exercised, they would represent approximately 3.29% of the issued Ordinary share capital of the Company. If the buyback authorities (both existing and sought) were exercised in full, and those shares were cancelled (but the Company's issued Ordinary share capital otherwise remained unaltered), then the number of options and awards to subscribe for shares outstanding as at 10 March 2026 would represent 3.66% of the reduced issued Ordinary share capital of the Company.

#### **Resolution 18 – Enabling the Company to call a general meeting on at least 14 days' notice**

This special resolution renews an authority given at last year's AGM and is required as a result of section 307A of the Companies Act 2006. The Company currently has power under its Articles of Association to call general meetings (other than an AGM) on at least 14 clear days' notice and would like to preserve this ability. In order to be able to do so, shareholders must first approve the calling of meetings on at least 14 days' notice. This resolution seeks such approval. The approval will be effective until the Company's AGM to be held in 2027, when it is intended that a similar resolution will be proposed. The shorter notice period would not be used as a matter of routine for general meetings, but only where the flexibility is merited by the business of the meeting and is thought to be to the advantage of the shareholders as a whole.

## NOTES

---

1. The Company specifies that only those holders of Ordinary shares registered in the register of members of the Company at the close of business on Tuesday 5 May 2026 (or, in the event that the meeting is adjourned, in the register of members at the close of business on the day that is two days (excluding any part of a day that is not a working day) before the day of the adjourned meeting) shall be entitled to vote at the meeting in respect of the number of Ordinary shares registered in their names at that time. Changes to entries on the register of members after that time shall be disregarded in determining the rights of any person to vote at the meeting.
2. A member of the Company entitled to attend, speak and vote at the AGM is entitled to appoint a proxy or proxies to attend, speak and vote on their behalf provided that if more than one proxy is appointed, each proxy is appointed to exercise rights attaching to different shares. A proxy need not be a member of the Company.
3. Members can appoint a proxy and give their voting instructions by any of the following means:
  - a) By submitting a proxy appointment online on the website of the Company's registrar, Equiniti, at [shareview.co.uk](https://shareview.co.uk), and logging into your Shareview Portfolio. Once you have logged in, click 'view' on the 'My Investments' page and then click on the link to vote and follow the on-screen instructions. If you have not registered for Shareview Portfolio, go to [shareview.co.uk](https://shareview.co.uk), click 'register' and enter the requested information. It is important that you register for Shareview Portfolio with enough time to complete the registration and authentication processes. To be a valid proxy appointment, the member's electronic message confirming the details of the appointment and completed in accordance with the online instructions, must be transmitted so as to be received by not later than 10.30am on Tuesday 5 May 2026 or, if the meeting is adjourned, no later than 48 hours (excluding any part of a day that is not a working day) before the time of the adjourned meeting;
  - b) By submitting a proxy appointment via CREST. Members who hold their shares in uncertificated form may use 'the CREST electronic proxy appointment service' to appoint a proxy electronically, as explained in Note 4 below;
  - c) By submitting a proxy appointment via the Proxymity platform. Members who are institutional investors may be able to appoint a proxy electronically via the Proxymity platform, as explained in Note 5 below; or
  - d) By completing and returning a paper form of proxy. A member may appoint a proxy by completing and returning a paper proxy form. Members who would like a paper proxy form may request one from Equiniti by calling +44 (0) 371 384 2412. To be valid, the paper proxy form should be sent to Equiniti, so as to arrive not later than 10.30am on Tuesday 5 May 2026 or, if the meeting is adjourned, no later than 48 hours (excluding any part of a day that is not a working day) before the time of the adjourned meeting. Members can return their completed proxy form in an envelope addressed to: FREEPOST RTHJ-CLLL-KBKU, Equiniti, Aspect House, Spencer Road, Lancing, BN99 8LU.  
  
Any power of attorney or other authority under which an appointment of proxy is signed or authenticated (or a copy which has been certified by a solicitor or a notary or in accordance with the Powers of Attorney Act 1971) should be sent to the relevant address specified in these notes for receipt of the proxy appointment, by the latest time indicated for receipt of such proxy appointment.
4.
  - a) CREST members who wish to appoint a proxy through the CREST electronic proxy appointment service may do so for the meeting and any adjournment(s) thereof by using the procedures described in the CREST Manual (available at [euroclear.com](https://euroclear.com)). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.
  - b) In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a "CREST Proxy Instruction") must be properly authenticated in accordance with Euroclear UK & International Limited's specifications and must contain the information required for such instructions, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by Equiniti as the issuer's agent (ID RA19) by no later than 10.30am on Tuesday 5 May 2026 or, if the meeting is adjourned, no later than 48 hours (excluding any part of a day that is not a working day) before the time of the adjourned meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.
  - c) CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
  - d) The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

## NOTES

---

5. If you are an institutional investor, you may be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Company's registrar. For further information regarding Proxymity, please go to [proxymity.io](https://proxymity.io). To be valid, a proxy appointment made via the Proxymity platform in accordance with the online instructions must be received by Equiniti no later than 10.30am on Tuesday 5 May 2026 or, if the meeting is adjourned, no later than 48 hours (excluding any part of a day that is not a working day) before the time of the adjourned meeting. Before you can appoint a proxy via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them, and they will govern the electronic appointment of your proxy.
6. In the case of joint holdings, any one holder may sign the proxy form. If more than one proxy form that is, or would otherwise be, valid is received in respect of the same share for use at the same meeting, the one which is received last (regardless of the date on which it is signed) will be treated as the valid form. If it is not possible to determine the order of receipt, none of them will be treated as valid.
7. Members who have returned proxy forms or who have registered the appointment of a proxy electronically in accordance with these notes are not precluded from attending the meeting and voting in person if they so wish.
8. Members (and any proxies or representatives they appoint) agree that by attending the meeting in person they are expressly requesting and are willing to receive communications (including any communications relating to the Company's Securities) made at the meeting.
9. All resolutions contained in this Notice of meeting will be put to vote on a poll. This will result in a more accurate reflection of the views of members by ensuring that every vote is recognised. On a poll, each member has one vote for every share held.
10. This Notice is sent for information only to holders of First Preference shares and Second Preference shares.
11. As at 10 March 2026 (being the last practicable date prior to the publication of this document) the Company's issued share capital consisted of 276,676,409 Ordinary shares of 25 pence each carrying one vote each, 125,327 First Preference shares which do not carry voting rights and 311,954 Second Preference shares which also do not carry voting rights. The total voting rights in the Company as at 10 March 2026 were, therefore, 276,676,409.
12. Members' personal data includes all data provided by members, or on their behalf, that relates to individuals as members, including name and contact details, votes cast and Shareholder Reference Number(s) (attributed to individual members by the Company). The Company determines the purposes for which and the manner in which individual members' personal data is to be processed. The Company and any third party to which it discloses the data (including the Company's registrar) may process personal data for the purposes of compiling and updating the Company's records, fulfilling its legal obligations and processing the rights exercised by members. A copy of the Company's privacy policy can be found at [morganadvancedmaterials.com/en-gb/privacy/](https://morganadvancedmaterials.com/en-gb/privacy/).
13. Any person to whom this Notice is sent who is a person nominated under section 146 of the Companies Act 2006 to enjoy information rights (a "Nominated Person") may have a right, under an agreement between him or her and the member by whom he or she was nominated, to be appointed (or to have someone else appointed) as a proxy for the meeting. If a Nominated Person has no such proxy appointment right or does not wish to exercise it, he or she may, under any such agreement, have a right to give instructions to the member as to the exercise of voting rights. The statement of the rights of members in relation to the appointment of proxies in Note 2 above does not apply to Nominated Persons. The rights described in that note can only be exercised by members of the Company.
14. A member that is a corporation may authorise one or more persons to act as its representative(s) at the AGM in accordance with section 323 of the Companies Act 2006. Any such representative should bring to the meeting written evidence of his or her appointment, such as a certified copy of a board resolution of, or a letter from, the corporation concerned confirming the appointment.
15. A member or members having a right to vote at the meeting and representing at least 5% of the total voting rights of the Company (see Note 11), or at least 100 members having a right to vote at the meeting and holding, on average, at least £100 of paid up share capital, may require the Company to publish on its website a statement setting out any matter that such members propose to raise at the meeting relating to the audit of the Company's latest accounts (including the Auditor's report and the conduct of the audit or any circumstances connected with the Company's former auditors ceasing to hold office since the Company's previous AGM). The Company cannot require the members concerned to pay its expenses in complying with sections 527 and 528 of the Companies Act 2006. The Company must forward any such statement to its Auditor by the time it makes the statement available on the website. The business which may be dealt with at the meeting includes any such statement.
16. Each member attending the meeting has the right to ask questions relating to the business being dealt with at the meeting which, in accordance with section 319A of the Companies Act 2006 and subject to some exceptions, the Company must cause to be answered. Members who wish to ask questions relating to the business of the AGM can also do so by sending them in advance of the meeting to [company.secretariat@morganplc.com](mailto:company.secretariat@morganplc.com), or by writing to the Company Secretary at our registered office address. To ensure that a response is received before the proxy appointment deadline, members should submit their questions before 5.00pm UK time on Monday 27 April 2026.
17. Copies of Directors' letters of appointment or service contracts are available for inspection for 15 minutes prior to, and during, the AGM.
18. The information required by section 311A of the Companies Act 2006 to be published in advance of the meeting, which includes the matters set out in this Notice and information relating to the voting rights of members, is available at [morganadvancedmaterials.com/2026AGM](https://morganadvancedmaterials.com/2026AGM).
19. A member may not use any electronic address provided by the Company in this document or with any proxy appointment form or in any website for communicating with the Company for any purpose in relation to the meeting other than expressly stated in it.





**Morgan Advanced Materials plc**

York House, Sheet Street

Windsor, Berkshire SL4 1DD

Registered in England and Wales No. 00286773

Tel: +44 (0)1753 837000

[www.morganadvancedmaterials.com](http://www.morganadvancedmaterials.com)